The American Society of Nephrology (ASN) and the FDA have jointly announced a partnership called the Kidney Health Initiative (KHI) to advance scientific understanding of the patient safety and treatment implications of new and existing medical products.
KHI will provide a forum for scientific collaboration, dialogue with patient groups, and others concerned about kidney health, intellectual partnerships, and public opportunities to foster exchange about potential advances in treatment, according to an ASN press release.
“In today’s complex world of new product development, establishing a deeper knowledge of disease stages and forging multi-disciplinary collaborations have become essential to finding safe and effective new therapies,” said Janet Woodcock, MD, Director of FDA’s Center for Drug Evaluation and Research.
“Together, ASN and FDA recognize the growing imperative to promote kidney health and improve patient safety,” said ASN President Ronald J. Falk, MD. “I foresee astonish benefit to patients as a result of increased exchange of knowledge through KHI.”
KHI will be fully operational by January 2013. ASN members will identify priorities for collaborative projects and other opportunities to advance kidney health and safety, according to the press release. Individuals interested in contributing are invited to contact [email protected].